AG-METOPROLOL-L TABLET

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

METOPROLOL TARTRATE

Pieejams no:

ANGITA PHARMA INC.

ATĶ kods:

C07AB02

SNN (starptautisko nepatentēto nosaukumu):

METOPROLOL

Deva:

25MG

Zāļu forma:

TABLET

Kompozīcija:

METOPROLOL TARTRATE 25MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

100/500

Receptes veids:

Prescription

Ārstniecības joma:

BETA-ADRENERGIC BLOCKING AGENTS

Produktu pārskats:

Active ingredient group (AIG) number: 0111923005; AHFS:

Autorizācija statuss:

APPROVED

Autorizācija datums:

2018-10-02

Produkta apraksts

_AG-Metoprolol-L tablets _
_Page 1_
_ _
_of 41_
_ _
PRODUCTMONOGRAPH
PR
AG-METOPROLOL-L
Metoprolol Tartrate Tablets USP
25mg, 50 mg and 100 mg film coated tablets,
USP
β-Adrenergic Receptor Blocking Agent
Angita Pharma Inc
1310 rue Nobel
Boucherville, Québec
J4B 5H3, Canada
Submission Control No: 266208
Date
of
Revision:
August 10, 2022
_AG-Metoprolol-L tablets _
_Page 2_
_ _
_of 41_
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................... 3
SUMMARY PRODUCT
INFORMATION
..........................................................................
3
INDICATIONS AND CLINICAL USE
...............................................................................
3
CONTRAINDICATIONS
....................................................................................................
4
WARNINGS AND
PRECAUTIONS
....................................................................................
5
ADVERSE REACTIONS
..................................................................................................
10
DRUG INTERACTIONS
..................................................................................................
12
DOSAGE AND ADMINISTRATION
...............................................................................
18
OVERDOSAGE
.................................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
............................................................. 21
STORAGE AND STABILITY
..........................................................................................
24
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................. 25
PART II: SCIENTIFIC
INFORMATION ..................................................................................
26
PHARMACEUTICAL INFORMATION
..........................................................................
26
CLINICAL TRIALS
...................................................................